ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Neonatology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1576979
This article is part of the Research TopicRetinopathy of prematurity: an update on pathophysiology, diagnostic methods and treatmentView all articles
Development and Validation of a Multivariate Nomogram for Predicting Retinopathy of Prematurity in Infants with Gestational Age ≤ 34 Weeks
Provisionally accepted- Department of Pediatrics, First Affiliated Hospital of Army Medical University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Purpose: To delineate risk factors and develop a predictive nomogram for retinopathy of prematurity (ROP) in infants with gestational age (GA)≤34 weeks.We conducted a comprehensive retrospective analysis of infants with GA ≤34 weeks, divided into ROP and non-ROP groups based on fundus screening results. Clinical and laboratory data were collected to identify risk factors associated with ROP. Multivariable logistic regression was performed to identify independent predictors, and a nomogram was developed to predict the occurrence of ROP in infants with GA ≤34 weeks.Results: Our analysis identified five independent risk factors for ROP in infants with GA ≤34 weeks: hypertensive disorders of pregnancy (HDP), number of blood transfusions, oxygen therapy time (OTT), oxygen therapy concentration (OTC) >50%, and blood glucose spikes in 2 the first postnatal week. These predictors were incorporated into a nomogram to estimate individual ROP risk. The predictive model achieved a C-index of 0.923 (95% CI: 0.888-0.959), indicating high predictive accuracy. Internal validation of the nomogram demonstrated excellent calibration and practical utility for clinical decision-making. Conclusions: The established predictive model, incorporating five key clinical parameters, offers clinicians a practical instrument to stratify ROP risk in neonates born at ≤34 weeks' gestation. This clinical tool demonstrates significant utility in guiding intervention protocols, potentially enhancing patient outcomes through early identification and optimized management strategies. Strengths and limitations of this study: Strengths 1. Identifies key clinical and laboratory risk factors associated with ROP, providing valuable insights for early diagnosis and intervention. 2. Develops and validates a robust predictive nomogram with high accuracy (C-index: 0.923) and clinical utility for neonatal care.3. Provides a practical and user-friendly predictive tool to aid clinical decision-making and optimize management strategies for ROP risk stratification.1. The study is limited to a single center, which may reduce the generalizability of the findings to broader neonatal populations.2. The predictive model has not been externally validated, necessitating further testing in diverse clinical environments to ensure robustness and applicability.
Keywords: premature infants, Retinopathy of Prematurity, Risk factors, predictive nomogram, Neonatal health
Received: 14 Feb 2025; Accepted: 23 Apr 2025.
Copyright: © 2025 Shen, Zheng, Sun and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sheng Chen, Department of Pediatrics, First Affiliated Hospital of Army Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.